

#### **Letter From The Executive Director**

Hello BBCIC Participants and Supporters,

WHAT A YEAR it has been!

At the **AMCP Nexus 2024** meeting we had our BBCIC In-Person (and virtual) meeting, and it was extremely engaging and energizing as usual. At one point we broke into groups to brainstorm about the biggest issues in biosimilars they anticipate in the near- and longer-term so that we can be sure BBCIC is prepared



BBCIC meeting during Nexus 2024.

to address the most pressing issues. This kind of group effort is essential to us as your multiple and variable viewpoints are key to the success of our consortium. We will continue to refine all of the feedback to aid in building our strategy for the next year and beyond. Visit us online to dive into a summary of our Nexus meeting.

**Read More** 

# **BBCIC Annual Meeting and Workshop**



BBCIC meeting during Nexus 2024.

On Oct. 14, BBCIC hosted our **7th Annual AMCP Nexus BBCIC Face-to-Face Meeting** in Las Vegas. We had 12 participants in person, and another 10 joined us online for what was an interesting and engaging afternoon. A few high points from the afternoon were:

- We started the afternoon by reviewing the results from our annual participant survey. (Thank you again to everyone who provided feedback!!)
- We then heard from our Science Committee chair about the 2024 Annual Research Topic Request process, and there was a brief discussion on the Science Committee rankings of topics that were submitted. The conversation then turned into a discussion of the top two topics that were submitted that BBCIC wants to move forward with starting in 2025:
  - Patient Experiences with Biologics and Biosimilars for IBD: A Qualitative Study

- A Survey of Key Stakeholder Perspectives on United States Biosimilar Market Sustainability
- The in-person and online participants were then split up into groups to focus on two brainstorming questions that we were looking to use to help guide our strategic planning moving forward:
  - What are the biggest issues that are important for biosimilars? Now?
    1-2 years? 5 years?
  - What are the biggest issues that are important for other targeted therapeutics?
- Even though it was getting late in the day for our Eastern Time zone participants, we still felt like we had great ideas flowing. More information will be shared on what was discussed!
- We closed out the day by receiving an update from our Carelon colleagues on our "Patient access to bevacizumab and trastuzumab biologics and the impact of biosimilars" research project, and BBCIC staff and consultants provided an update to the group on our two active FDA Grants.

Thank you for your enthusiasm and engagement!

## **New Publications**



We are pleased to announce we have one newly published manuscript and one new manuscript that has been accepted for publication by the *Journal of Managed Care* & *Specialty Pharmacy*!

The newly published manuscript can be found at:

<u>Utilization and Patient Characteristics for the Trastuzumab Reference and Biosimilars, and Other HER2 Inhibitors in the United States</u>


Read on JMCP

### **Current Research**

Please visit our <u>research page</u> for descriptions and status of our current and upcoming research!

Learn More

## **Abstract Tracker**



BBCIC | 675 North Washington Street, Suite 220 | Alexandria, VA, 22314

Manage Preferences







